SY21-3 RET-altered cancers: toward tumor agnostic therapy

Abstract

RRecently, highly potent and RET-specific inhibitors were translated to the clinic. In Japan, A RET-specific inhibitor, selpercatinib, has been implemented for RET-fusion positive non-small cell lung carcinoma in December, 2021. The RET gene is an oncogene that encodes a receptor-type tyrosine kinase, and actually functions as a driver gene for various cancer types other than lung cancer. In fact, clinical trials of RET inhibitors have confirmed their therapeutic effects in various cancer types, including pancreatic, breast, and ovarian cancers, and it is expected that they will be implemented as a tumor-agnostic treatment.